Palatin reports preliminary Q4 Vyleesi sales up 20% sequentially

Palatin Technologies announced preliminary Q4 Vyleesi product revenue results. Vyleesi is the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. Preliminary Vyleesi product revenue results for 4Q23: gross product revenue was $4.1M, an increase of 20% over 3Q23, and an increase of 78% over the comparable quarter in 2022, net product revenue was $1.7M, an increase of 42% over 3Q23, and an increase of 122% over the comparable quarter in 2022, prescriptions dispensed increased 14% over 3Q23, and an increase of 89% over the comparable quarter in 2022. Key operating and commercial metrics, including new patient starts, refill rates, commercial insurance reimbursement, net revenue per prescription dispensed, and new healthcare prescribers, continued with positive results and trends, versus the third quarter in 2023, and comparable quarter in 2022.